Docetaxel is an antineoplastic agent that has a unique mechanism of action as an inhibitor of cellular mitosis and that currently plays a central role in the therapy of many solid tumor including breast and lung cancer. Therapy with docetaxel has been associated with a low rate of serum enzyme elevations and rarely to instances of acute hepatic necrosis generally due to severe hypersensitivity reactions or sepsis. Docetaxel has not been clearly linked to cases of idiopathic, clinically apparent acute liver injury.
Docetaxel (doe" se tax' el) is a complex diterpenoid molecule that contains a central 8-member taxane ring. Docetaxel is a semisynthetic analogue of paclitaxel and was initially isolated from the needles of the European Yew tree (Taxus baccata). It is a potent antineoplastic agent and its mechanism of action appears to be mediated by its binding to microtubulin, which is important in the mitototic phase of cell division. The binding of docetaxel prevents the disassembly of the cytoskeletal microtubules, preventing cell division and leading to cell death. Docetaxel was approved for use in the United States in 1996 and it remains an important agent in the therapy of several neoplasms including breast, gastric, prostate, head and neck, and non-small cell lung cancer. Docetaxel is available in solution for injection generically and under the brand names such as Taxotere and Docefrez. Docetaxel is administered intravenously, typically as one hour infusions every three weeks in cycles in combination with other antineoplastic agents. The dose varies by indication and body weight. Preexisting liver disease is considered a relative contraindication of its use. Side effects are common and include diarrhea, nausea, vomiting, mucositis, fatigue, myalgias, skin rash, alopecia, phlebitis, bone marrow suppression, fluid retention, cardiomyopathy, peripheral neuropathy and hypersensitivity reactions. Premedication with oral corticosteroids is recommended to prevent severe hypersensitivity reactions.
Docetaxel has been associated with serum aminotransferase elevations in up to half of patients, but values greater than 5 times the upper limit of normal (ULN) occurr in less than 2%. Similar rates of alkaline phosphatase elevations and occasional mild bilirubin elevations also occur. The abnormalities are usually asymptomatic, mild and self-limited, rarely requiring dose modification or discontinuation. Despite the frequency of serum enzyme elevations during therapy, clinically apparent liver injury from docetaxel is rare. Individual case reports of severe acute hepatic necrosis attributed to docetaxel have been published, but most likely represent ischemic liver injury due to a severe hypersensitivity reaction to the initial infusion of docetaxel, the typical case arising within 1 to 2 days of initiating therapy and associated with rapid, marked rises in serum aminotransferase levels and early hepatic and multiorgan failure with only mild jaundice. Because docetaxel is often given with other antineoplastic agents, liver injury arising during therapy cannot always be attributed reliably to docetaxel as opposed to another specific agent. Furthermore, docetaxel in combination with other antineoplastic agents may be associated with reactivation of hepatitis B, increased risk of opportunistic viral infections, sinusoidal obstruction syndrome and sepsis, any of which can cause liver test abnormalities or clinically apparent liver injury. Convincing cases of idiosyncratic acute liver injury have not been reported with docetaxel use.
Likelihood score: C (probable cause of acute hepatic necrosis associated with hypersensitivity reaction to initial infusion).
Mechanism of Injury
Docetaxel likely has a direct toxic effect on hepatocytes, accounting for the frequency of serum enzyme elevations during therapy, particularly with higher doses. Docetaxel is metabolized in the liver by the cytochrome P450 system, predominantly CYP 3A4 and 3A5.
Outcome and Management
The serum aminotransferase elevations that occur on docetaxel therapy are usually self-limited and do not require dose modification or discontinuation of therapy. There have been no cases of idiosyncratic, clinically apparent or severe acute liver injury linked to docetaxel therapy in the published literature.
REPRESENTATIVE TRADE NAMES
– Generic, Taxotere®
Product labeling at DailyMed, National Library of Medicine, NIH
||CAS REGISTRY NUMBER
References updated: 15 January 2018
Zimmerman HJ. Hepatotoxic effects of oncotherapeutic and immunosuppressive
agents. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other
chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp.673-708.
(Textbook of hepatotoxicity published in 1999; docetaxel is
DeLeve LD. Cancer chemotherapy. In, Kaplowitz N, DeLeve LD, eds.
Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 549-68. (Review of hepatotoxicity of cancer chemotherapeutic agents; the taxanes are
not specifically discussed).
Chabner BA, Bertino J, Clearly J, Ortiz T, Lane A, Supko JG, Ryan DP.
Taxanes. Cytotoxic agents. Chemotherapy of neoplastic diseases. In, Brunton LL,
Chabner BA, Knollman BC, eds. Goodman & Gilman's the pharmacological basis
of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1707-9. (Textbook of pharmacology and therapeutics).
Blaney SM, Seibel NL, O'Brien M, Reaman GH, Berg SL, Adamson PC, Poplack DG,
et al. Phase I trial of docetaxel administered as a 1-hour infusion in children
with refractory solid tumors: a collaborative pediatric branch, National Cancer
Institute and Children's Cancer Group trial. J Clin Oncol 1997; 15: 1538-43. PubMed Citation (44 children with refractory solid tumors were given 103 courses of
docetaxel every 21 days; major dose limiting toxicities were neutropenia, mild
ALT elevations [<3 times ULN] occurred, but frequency and details were not
Von Hoff DD. The taxoids: same roots, different drugs. Semin Oncol 1997; 4(4
Suppl 13): S13-3-S13-10. PubMed Citation (Review of the development of paclitaxel and docetaxel, clinical use,
efficacy and toxicity stressing the differences between the two taxoids, which
are due largely to differences in pharmacokinetics).
Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of
hormone-refractory prostate cancer: preliminary results. Semin Oncol 1999; 26 (5
Suppl 17): 14-8. PubMed Citation (35
patients with prostate cancer were treated with docetaxel every 3 weeks [average
of 6 cycles]; one had marked ALT elevations, but also had liver
Crown J. A review of the efficacy and safety of docetaxel as monotherapy in
metastatic breast cancer. Semin Oncol 1999; 26 (1 Suppl 3): 5-9. PubMed Citation (Brief review of safety and efficacy of docetaxel in advanced breast
cancer; no discussion of hepatotoxicity or ALT elevations).
Burris HA 3rd. Single-agent docetaxel(Taxotere) in randomized phase III
trials. Semin Oncol 1999; 26 (3 Suppl 9): 1-6. PubMed Citation (Review of 3 randomized trials of docetaxel vs standard chemotherapy in
women with breast cancer; adverse events were common, but hepatotoxicity was not
Fumoleau P. Efficacy and safety of docetaxel in clinical trials. Am J Health
Syst Pharm 1997; 54 (24 Suppl 2): S19-24. PubMed Citation (Overall response rates to docetaxel and paclitaxel in advanced breast
cancer ranged from 29-68% of patients; major dose related toxicities included
neutropenia, mucositis, cardiomyopathy and fluid retention; hepatotoxicity was
Alexandre J, Bleuzen P, Bonneterre J, Sutherland W, Misset JL, Guastalla J,
Viens P, et al. Factors predicting for efficacy and safety of docetaxel in a
compassionate-use cohort of 825 heavily pretreated advanced breast cancer
patients. J Clin Oncol 2000; 18: 562-73. PubMed Citation (Among 825 patients with breast cancer undergoing therapy with docetaxel,
the risk for febrile neutropenia was increased in those with liver dysfunction
as defined by ALT or AST >1.5 and Alk P >3 times ULN [odds ratio
Tomassini E, Muhizi J, al Raheb K, Steinbach G, Bemer M, Platini C.
[Fulminant hepatocellular necrosis following administration of docetaxel].
Presse Med 2001; 30: 634. French. PubMed Citation (52
year old woman with metastatic breast cancer developed jaundice and stupor 72
hours after an initial infusion of docetaxel [bilirubin 6.8 mg/dL, ALT 5540 U/L,
GGT 116 U/L, protime 18 sec], with death from multiorgan failure and autopsy
showing massive necrosis).
Venturini M, Del Mastro L, Garrone O, Angiolini C, Merlano M, Bergaglio M,
Tolino G, et al. Phase I, dose-finding study of capecitabine in combination with
docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer.
Ann Oncol 2002; 13: 546-52. PubMed Citation (Among 23 women with advanced breast cancer treated with 139 cycles of
docetaxel, capecitabine and epirubicin, 2 were withdrawn because of hepatic
Yeo W, Mok TS, Tse KK, Kwan WH, Lam KC, Ho WM, Chiu SK, et al. Phase II
study of docetaxel and epirubicin in Chinese patients with metastatic breast
cancer. Anticancer Drugs 2002; 13: 655-62. PubMed Citation (Among 46 patients treated with docetaxel and epirubicin, 6 [13%] developed
abnormal ALT levels including two with hepatitis B reactivation, the 4 without
hepatitis B being mild and transient).
Sundar S, Chan SY. Cholestatic jaundice and pseudomembranous colitis
following combination therapy with doxorubicin and docetaxel. Anticancer Drugs
2003; 14: 327-9. PubMed Citation (45
year old woman with advanced breast cancer developed febrile neutropenia after 2
cycles of docetaxel and doxorubicin with subsequent pseudo-membranous colitis
and jaundice [peak bilirubin 5.3 mg/dL, ALT 46 U/L, Alk P 3436 U/L], resolving
within 2 months).
Pelegrino, Calvo L, Mayordomo JI, Florian J, Vazquez S, Arcusa A,
Martn-Richard M, et al.; Spanish Group for Breast Cancer Research (GEICAM).
Gemcitabine plus docetaxel administered every other week as first-line treatment
of metastatic breast cancer: preliminary results from a phase II trial. Semin
Oncol 2004; 31 (2 Suppl 5): 20-4. PubMed Citation (Among 35 patients with metastatic breast cancer treated with up to 10
cycles of docetaxel and gemcitabine, 51% had aminotransferase elevations, which
were >5 times ULN in 6%, but largely asymptomatic and
Goodin S, Medina P, Capanna T, Shih WJ, Abraham S, Winnie J, Doyle-Lindrud
S, et al. Effect of docetaxel in patients with hormone-dependent
prostate-specific antigen progression after local therapy for prostate cancer. J
Clin Oncol 2005; 23: 3352-7. PubMed Citation (Among 25 patients with advanced prostate cancer given docetaxel in 3 week
cycles, one had dose reduction for ALT elevations >5 times ULN).
Kaira K, Takise A, Minato K, Iwasaki Y, Ishihara S, Takei Y, Tsuchiya S, et
al. Phase II study of weekly docetaxel and cisplatin in patients with non-small
cell lung cancer. Anticancer Drugs 2005; 16: 455-60. PubMed Citation (Among 40 patients with lung cancer treated with weekly docetaxel and
cisplatin, 2 had ALT elevations >5 times ULN leading to dose reduction in
Cao Y, Wang ZQ, Guo Y, Feng FY, Hu XH, Xiong JP, Tang GD, et al. [A
randomized control clinical trial of Euruikang (docetaxel) in treatment of
advanced non-small cell lung cancer (NSCLC)]. Ai Zheng 2006; 25: 999-1002.
Chinese. PubMed Citation
Kasahara K, Kimura H, Shibata K, Araya T, Sone T, Oribe Y, Furusho S, et al.
A phase II study of combination chemotherapy with docetaxel and carboplatin for
patients with advanced or metastatic non-small cell lung cancer. Anticancer Res
2006; 26: 3723-8. PubMed Citation (Among 40 patients with advanced lung cancer treated with docetaxel and
carboplatin, 6 [15%] had ALT elevations which were above 5 times ULN in
Liu DG, Peng RJ, Feng FY, Hu XH, Tang GD, Xiong JP, Zhao HY, et al.
[Randomized controlled trial of two kinds of home-produced docetaxel in China
for advanced breast cancer]. Ai Zheng 2006; 25: 1557-60. Chinese. PubMed Citation (Comparison of two formulations of docetaxel in 67 patients with advanced
breast cancer found that transient ALT and AST elevations were
Sinibaldi VJ, Elza-Brown K, Schmidt J, Eisenberger MA, Rosenbaum E, Denmeade
SR, Pili R, et al. Phase II evaluation of docetaxel plus exisulind in patients
with androgen independent prostate carcinoma. Am J Clin Oncol 2006; 29: 395-8. PubMed
Citation (Among 14 patients with prostate cancer treated with docetaxel
and exisulind, 21% had aminotransferase elevations above 5 times ULN).
Aoki H, Ishidoya S, Ito A, Endoh M, Shimazui T, Arai Y. Experience of the
treatment with gemcitabine, docetaxel, and carboplatin(GDC) chemotherapy for
patients with small-cell carcinoma of the prostate. Int J Urol 2006; 13: 1254-8. PubMed
Citation (Two patients with advanced prostate cancer were treated with
docetaxel in combination with gemcitabine and carboplatin; one developed acute
liver failure several months after a fifth cycle which was attributed to herpes
Ohlmann CH, Kohlmorgen S, Sahi D, Engelmann U, Heidenreich A. [Lethal course
after chemotherapy with docetaxel. Acute liver failure with accompanying
erythema multiforme major]. Urologe A 2007; 46: 1425-7. German. PubMed Citation (67
year old man with prostate cancer developed Stevens-Johnson Syndrome,
neutropenia and thrombocytopenia after 5 weekly infusions of docetaxel, with
subsequent rise in liver tests and jaundice that progressed to hepatic failure
and death; few details provided).
Chen JP, Lo Y, Yu CJ, Hsu C, Shih JY, Yang CH. Predictors of toxicity of
weekly docetaxel in chemotherapy-treated non-small cell lung cancers. Lung
Cancer 2008; 60: 92-7. PubMed Citation (Retrospective analysis of toxicity of 455 cycles of docetaxel in 155
patients with non-small cell lung cancer; 67 patients were withdrawn for
toxicity, 2 were liver related; preexisting hepatitis B and C were risk factors
James J, Murry DJ, Treston AM, Storniolo AM, Sledge GW, Sidor C, Miller KD.
Phase I safety, pharmacokinetic and pharmacodynamic studies of
2-methoxyestradiol alone or in combination with docetaxel in patients with
locally recurrent or metastatic breast cancer. Invest New Drugs 2007; 25: 41-8. PubMed
Citation (Among 15 women with advanced breast cancer treated with
docetaxel and 2-methoxyestradiol, 3 [20%] had ALT elevations, which resolved
with dose reductions in 2 and stopping docetaxel in 1).
Minami H, Kawada K, Sasaki Y, Tahara M, Igarashi T, Itoh K, Fujii H, et al.
Population pharmacokinetics of docetaxel in patients with hepatic dysfunction
treated in an oncology practice. Cancer Sci 2009; 100: 144-9. PubMed Citation (Analysis of pharmacokinetics of docetaxel in 200 patients found that liver
test abnormalities were associated with delayed clearance and recommended 20-40%
reduction in dose).
Kobayashi K, Yokonishi T, Ito Y, Matsumoto T, Umemoto S, Osaka K, Nakamura
M, et al. [Low-dose docetaxel, estramustine and dexamethasone combination
chemotherapy for hormone-refractory prostate cancer]. Hinyokika Kiyo 2010; 56:
203-7. Japanese. PubMed Citation (Among 62 patients with advanced prostate cancer treated with docetaxel,
estramustine and dexamethasone for an average of 11 cycles, only 1 had transient
ALT elevation >5 times ULN).
Wang Z, Liang X, Yu J, Zheng X, Zhu Y, Yan Y, Dong N, et al. Non-genetic
risk factors and predicting efficacy for docetaxel--drug-induced liver injury
among metastatic breast cancer patients. J Gastroenterol Hepatol 2012; 27:
Citation (Among 647 women with breast cancer treated with docetaxel, 67
[10%] developed liver injury [27% with jaundice], with a median time to onset of
14 days; risk factors were menopausal status, hepatitis B markers, and presence
of liver metastases).
Liang X, Zhang J, Zhu Y, Lu Y, Zhou X, Wang Z, Yu J, et al. Specific genetic
polymorphisms of IL10-592 AA and IL10-819 TT genotypes lead to the key role for
inducing docetaxel-induced liver injury in breast cancer patients. Clin Transl
Oncol 2013; 15: 331-4. PubMed Citation (Among 129 patients with metastatic breast cancer treated with docetaxel,
there were significant associations between specific polymorphisms of IL10, but
not tumor necrosis factor and 40 instances of acute liver injury; although the
associations were slight).
Mandaliya H, Baghi P, Prawira A, George MK. A rare case of paclitaxel and/or
trastuzumab induced acute hepatic necrosis. Case Rep Oncol Med 2015; 2015:
825603. PubMed Citation (62 year old woman with metastatic breast cancer
received 4 cycles of doxorubicin and cyclophosphamide and developed pulmonary
edema and respiratory failure within 12 hours of an initial infusion of paclitaxel and
trastuzumab, dying one day later and autopsy showing acute hepatic necrosis; no
liver test results provided).
N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.;
United States Drug Induced Liver Injury Network. Features and outcomes of 899
patients with drug-induced liver injury: The DILIN Prospective Study.
Gastroenterology 2015; 148: 1340-52.e7. PubMed
899 cases of drug induced liver injury enrolled in a US prospective study
between 2004 and 2013, 49 [5.5%] were attributed to antineoplastic agents of
which only 1 was due to a taxane [docetaxel]).
Oudard S, Fizazi K, Sengeløv L, Daugaard G, Saad F, Hansen S, Hjälm-Eriksson
M, et al. Cabazitaxel versus docetaxel as first-line therapy for patients with
metastatic castration-resistant prostate cancer: a randomized phase III
trial-FIRSTANA. J Clin Oncol 2017; 35: 3189-97. PubMed Citation (Among
1,168 patients witih metastatic prostate cancer treated with cabazitaxel or
docetaxel, overall survival rates were similar while adverse events were higher
in a higher dose arm of cabazitaxel; ALT elevations and hepatotoxicity were not
Top of page
OTHER REFERENCE LINKS
Top of page